A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine-Reference-Cited by-同舟云学术

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine

Published:2017-07 Issue:3 Volume:3 Page:179-190
ISSN:2056-4538
Container-title:The Journal of Pathology: Clinical Research
language:en
Short-container-title:J Path: Clin Res

Author:

Kalloger Steve E¹²,Riazy Maziar²,Tessier-Cloutier Basile²^ORCID,Karasinska Joanna M¹,Gao Dongxia³,Peixoto Renata D⁴,Samimi Setareh⁴,Chow Christine³,Wong Hui-Li¹⁴,Mackey John R⁵,Renouf Daniel J¹⁴⁶,Schaeffer David F¹²³⁷

Affiliation:

1. Pancreas Centre BC; Vancouver BC Canada

2. Department of Pathology & Laboratory Medicine; University of British Columbia; Vancouver, BC Canada

3. Genetic Pathology Evaluation Centre; Vancouver, BC Canada

4. Department of Medical Oncology; British Columbia Cancer Agency; Vancouver, BC Canada

5. Cross Cancer Institute and University of Alberta; Edmonton, AB Canada

6. Department of Medicine; University of British Columbia; Vancouver, BC Canada

7. Division of Anatomical Pathology; Vancouver General Hospital; Vancouver, BC Canada

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Reference21 articles.

1. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial;Neoptolemos;Lancet,2001

2. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial;Oettle;JAMA,2007

3. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma;Marcé;Haematologica,2006

4. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells;Cano-Soldado;Biochem Pharmacol,2008

5. CN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer;Sève;Lung Cancer,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. hENT1 as a Predictive Biomarker in PDAC—Response;Clinical Cancer Research;2023-08-01

2. Concordance of human equilibrative nucleoside transporter‐1 expressions between murine ( 10D7G2 ) and rabbit ( SP120 ) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial;Cancer Reports;2021-07-29

3. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial;Pancreatology;2021-06

4. Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue;Biomarker Insights;2021-01

5. “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer;Cancers;2020-10-31